Wave Life Sciences Ltd. (NASDAQ:WVE) Q3 2023 Earnings Conference Call November 9, 2023 8:30 AM ET

Company Participants

Kate Rausch - Vice President, Investor Relations & Corporate Affairs

Paul Bolno - President & Chief Executive Officer

Anne-Marie Li-Kwai-Cheung - Chief Development Officer

Kyle Moran - Chief Financial Officer

Conference Call Participants

Steve Seedhouse - Raymond James

Salim Syed - Mizuho

Joseph Schwartz - Leerink Partners

Eun Yang - Jefferies

Operator

Good morning and welcome to Wave Life Sciences Third Quarter 2023 Financial Results Conference Call. At this time, all participants are in a listen-only mode. As a reminder, this call is being recorded and webcast.

Now I'll turn the call over to Kate Rausch, Vice President, Investor Relations and Corporate Affairs. Please go ahead.

Kate Rausch

Thank you, operator. Good morning and thank you for joining us today to discuss our recent business progress and review the third quarter 2023 financial results. Joining me today are Dr. Paul Bolno, President and Chief Executive Officer; Kyle Moran, Chief Financial Officer; Anne-Marie Li-Kwai-Cheung, Chief Development Officer; Dr. Ginnie Yang, SVP Translational Medicine; and Dr. Chandra Vargeese Chief Technology Officer. The press release issued this morning is available on the Investors Section of our website www.wavelifesciences.com.

Before we begin I would like to remind you that discussions during this conference call will include forward-looking statements. These statements are subject to several risks and uncertainties that could cause our actual results to differ materially from those described in these forward-looking statements. The factors that could cause actual results to differ are discussed in the press release issued today and in our SEC filings including our annual report on Form 10-K for the year ended December 31, 2022 and our quarterly report on Form 10-Q for the quarter ended September 30, 2023. We undertake no obligation to update or revise any forward-looking statement for any reason.

I'd now like to turn the call over to Paul.

Paul Bolno

Thanks, Kate. Good morning and thank you all for joining us on today's call. I will begin with opening remarks. Next Anne-Marie will provide an update on our clinical trials. And finally, Kyle will review our financials. We will then open up the call for questions. Chandra and Ginnie will also be available for questions.

In the third quarter our team made tremendous progress advancing our pipeline of novel RNA medicine. Since our last update we have brought our first-in-class RNA editing therapeutic program WVE-006 for AATD into the clinic. We outlined our strategy for growth at our Annual R&D Day including announcing a new wholly-owned siRNA program targeting INHBE for metabolic disorders including obesity and we continue to advance our clinical trials in DMD and HD.